Phase 1 Trial of ANK-700 for RRMS Advancing to Multiple Doses

Phase 1 Trial of ANK-700 for RRMS Advancing to Multiple Doses

315685

Phase 1 Trial of ANK-700 for RRMS Advancing to Multiple Doses

A Phase 1 clinical trial investigating the safety and tolerability of Anokion‘s ANK-700 in people with relapsing-remitting multiple sclerosis (RRMS) has begun enrolling patients for its multiple ascending dose part. This opening of the study’s second part follows positive safety signs in patients given the one of two doses of ANK-700 in its single ascending dose first part. Recruitment for multiple ascending doses will run alongside enrollment of a third single ascending dose group in the MoveS-it trial…

You must be logged in to read/download the full post.